Meeting
2018 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
Authors
Taavi Neklesa
Arvinas, New Haven, CT
Taavi Neklesa , Lawrence B Snyder , Ryan R Willard , Nicholas Vitale , Kanak Raina , Jennifer Pizzano , Deborah A Gordon , Mark Bookbinder , Jennifer Macaluso , Hanqing Dong , Zheng Liu , Caterina Ferraro , Gan Wang , Jing Wang , Craig M Crews , John Houston , Andrew P Crew , Ian Taylor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 381)
DOI
10.1200/JCO.2018.36.6_suppl.381
Abstract #
381
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2017 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi K Neklesa
Poster
2014 Genitourinary Cancers Symposium
Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer.
First Author: Paul Toren
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang